Content Status
Type
Linked Node
Management of Hepato-toxicity During Treatment with H Mono/Poly DR-TB Regimen
Learning ObjectivesManagement of Hepato-toxicity During Treatment with H Mono/Poly DR-TB Regimen
H5Content
Content
The management of hepatotoxicity during treatment with H mono/poly Drug-resistant TB (DR-TB) regimen is elaborated in the figure below.
Figure: Management of hepatotoxicity during treatment with H mono/poly DR-TB regimen; Source: Guidelines for PMDT, India 2021, p89.
Abbr: AST: Aspartate aminotransferase; ALT: Alanine transaminase; FQ: Fluoroquinolone; R: Rifampin; Z: Pyrazinamide; UNL: Upper Normal Level
Resources
- Guidelines for Programmatic Management of Drug-resistant Tuberculosis in India, March 2021.
- WHO Consolidated Guidelines on Tuberculosis: Module 4 - Treatment: Drug-resistant TB Treatment, 2020.
- Technical and Operational Guidelines for TB in India, 2016.
Kindly provide your valuable feedback on the page to the link provided HERE
LMS Page Link
Content Creator
Reviewer
- Log in to post comments